MCID: PNC008
MIFTS: 39

Pancreatic Endocrine Carcinoma

Categories: Cancer diseases, Endocrine diseases, Neuronal diseases

Aliases & Classifications for Pancreatic Endocrine Carcinoma

MalaCards integrated aliases for Pancreatic Endocrine Carcinoma:

Name: Pancreatic Endocrine Carcinoma 12 15 17 71
Malignant Neoplasm of Islets of Langerhans 12
Pancreatic Neuroendocrine Carcinoma 12
Carcinoma of Endocrine Pancreas 12
Carcinoma, Islet Cell 43
Islet Cell Carcinoma 12
Carcinoma Islet Cell 54

Classifications:



External Ids:

Disease Ontology 12 DOID:1798
ICD9CM 34 157.4
MeSH 43 D018273
NCIt 49 C3770
SNOMED-CT 67 60346004 93843007
ICD10 32 C25.4
UMLS 71 C1328479

Summaries for Pancreatic Endocrine Carcinoma

Disease Ontology : 12 An islet cell tumor that has material basis in epithelial cells.

MalaCards based summary : Pancreatic Endocrine Carcinoma, also known as malignant neoplasm of islets of langerhans, is related to glucagonoma and duodenal ulcer. An important gene associated with Pancreatic Endocrine Carcinoma is MEG3 (Maternally Expressed 3), and among its related pathways/superpathways are Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers and cAMP signaling pathway. The drugs Oxaliplatin and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include pancreas, pituitary and liver.

Related Diseases for Pancreatic Endocrine Carcinoma

Diseases related to Pancreatic Endocrine Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 350)
# Related Disease Score Top Affiliating Genes
1 glucagonoma 30.3 SST GAST CHGA
2 duodenal ulcer 30.0 SST INS GAST
3 peptic ulcer disease 30.0 SST MEN1 GAST
4 lung large cell carcinoma 29.9 SYP NCAM1 CHGA
5 ampulla of vater neoplasm 29.9 SYP SST CHGA
6 cholelithiasis 29.9 SST INS GAST
7 hyperparathyroidism 29.6 PTHLH MEN1 GAST CHGA
8 large cell carcinoma 29.6 SYP PTHLH NCAM1 CHGA
9 carcinoid syndrome 29.5 SYP SST MEN1 CHGA
10 merkel cell carcinoma 29.4 SYP SSTR2 SST NCAM1 CHGA
11 somatostatinoma 29.3 SSTR2 SST SPINK5 PPY MEN1 INS
12 acinar cell carcinoma 29.3 SYP SERPINA3 GAST CHGA AFP
13 tuberous sclerosis 29.3 SYP SST INS CHGA
14 acromegaly 29.1 SSTR5 SSTR2 SST MEN1 INS
15 primary hyperparathyroidism 28.9 PTHLH MEN1 INS GAST CHGA
16 pheochromocytoma 28.9 SYP SST NCAM1 MEN1 MEG3 CHGA
17 vipoma 28.7 SST SPINK5 MEN1 GAST CHGA
18 carcinoid tumors, intestinal 28.7 SYP SSTR2 SST MEN1 GAST CHGA
19 zollinger-ellison syndrome 28.3 SST PPY MEN1 GAST CHGA
20 insulinoma 28.2 SSTR5 SSTR2 SST MEN1 INS GCG
21 neuroendocrine carcinoma 28.2 SYP SST NCAM1 MEN1 GCG GAST
22 pancreatic cholera 28.2 SST PPY MEN1 GCG GAST CHGA
23 gastrinoma 28.1 SSTR5 SSTR2 SST MEN1 INS GAST
24 islet cell tumor 28.0 SYP SST SPINK5 SERPINA3 PTHLH PPY
25 neuroendocrine tumor 28.0 SYP SSTR2 SST NCAM1 MEN1 GCG
26 pancreatic cancer 27.9 SSTR2 SST PTHLH MEN1 MEG3 INS
27 multiple endocrine neoplasia, type i 26.6 SYP SST SPINK5 PPY MEN1 INS
28 neuroendocrine carcinoma of pancreas 11.4
29 lung combined type small cell carcinoma 10.5 SYP NCAM1
30 hypoganglionosis 10.5 SYP NCAM1
31 cerebellopontine angle primitive neuroectodermal 10.5 SYP NCAM1
32 tsh producing pituitary tumor 10.5 SSTR5 SSTR2
33 pineal region meningioma 10.5 SSTR5 SSTR2
34 thymus sarcomatoid carcinoma 10.5 SYP AFP
35 biliary tract benign neoplasm 10.5 SYP NCAM1
36 prostate stromal sarcoma 10.5 SYP NCAM1
37 mature teratoma of the ovary 10.4 SYP AFP
38 ovarian cystic teratoma 10.4 SYP AFP
39 bladder lateral wall cancer 10.4 SYP NCAM1
40 nasal cavity olfactory neuroblastoma 10.4 SYP NCAM1
41 oncogenic osteomalacia 10.4 SSTR5 PTHLH
42 adult type testicular granulosa cell tumor 10.4 NCAM1 AFP
43 non-gestational ovarian choriocarcinoma 10.4 NCAM1 AFP
44 ectopic cushing syndrome 10.4 SYP SST
45 cerebral lymphoma 10.4 SSTR5 SST
46 ovarian germ cell teratoma 10.4 SYP AFP
47 posterior pituitary gland neoplasm 10.4 SYP SSTR5 SSTR2
48 infected hydrocele 10.4 NCAM1 AFP
49 gastric antral vascular ectasia 10.4 SST GAST
50 lethal midline granuloma 10.4 SERPINA3 NCAM1

Graphical network of the top 20 diseases related to Pancreatic Endocrine Carcinoma:



Diseases related to Pancreatic Endocrine Carcinoma

Symptoms & Phenotypes for Pancreatic Endocrine Carcinoma

Drugs & Therapeutics for Pancreatic Endocrine Carcinoma

Drugs for Pancreatic Endocrine Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 94)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 2, Phase 3 61825-94-3 5310940 9887054 6857599 43805
2
leucovorin Approved Phase 2, Phase 3 58-05-9 6006 143
3
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
4
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2
5
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
6
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
7
Sunitinib Approved, Investigational Phase 3 341031-54-7, 557795-19-4 5329102
8
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
9 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
10 Immunologic Factors Phase 2, Phase 3
11 Immunosuppressive Agents Phase 2, Phase 3
12 Vitamin B9 Phase 2, Phase 3
13 Folate Phase 2, Phase 3
14 Antimetabolites Phase 2, Phase 3
15 Liver Extracts Phase 3
16 Cola Phase 3
17 Narcotics Phase 3
18 Anesthetics Phase 3
19 Anesthetics, General Phase 3
20 Analgesics, Opioid Phase 3
21 Adjuvants, Anesthesia Phase 3
22 Central Nervous System Depressants Phase 3
23 Anesthetics, Intravenous Phase 3
24 Analgesics Phase 3
25 Angiogenesis Inhibitors Phase 3
26
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
27
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
28
Streptozocin Approved, Investigational Phase 2 18883-66-4 29327
29
Melphalan Approved Phase 2 148-82-3 4053 460612
30
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
31
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
32
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
33
Etoposide Approved Phase 2 33419-42-0 36462
34
nivolumab Approved Phase 2 946414-94-4
35
Ipilimumab Approved Phase 2 477202-00-9
36
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
37
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
38
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
39
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
40
Pancrelipase Approved, Investigational Phase 2 53608-75-6
41
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
42
Lenograstim Approved, Investigational Phase 2 135968-09-1
43
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
44
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
45
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 68-26-8, 11103-57-4, 22737-96-8 445354 9904001
46
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
47
Imetelstat Investigational Phase 2 868169-64-6
48 Insulin, Globin Zinc Phase 2
49 insulin Phase 2
50 Topoisomerase Inhibitors Phase 2

Interventional clinical trials:

(show top 50) (show all 52)
# Name Status NCT ID Phase Drugs
1 A Pilot Study of FOLFOX in Combination With Bevacizumab in Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
2 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
3 A Phase III Randomized, Double-Blind Study Of Sunitinib (SU011248, SUTENT) Versus Placebo In Patients With Progressive Advanced/Metastatic Well-Differentiated Pancreatic Islet Cell Tumors Terminated NCT00428597 Phase 3 sunitinib malate;Placebo
4 A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma Completed NCT00781911 Phase 2 depot octreotide
5 An Open Label, Stratified, Single-arm Phase II Study of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumor (NET) After Failure of Cytotoxic Chemotherapy Completed NCT00363051 Phase 2 Everolimus 10 mg;Octreotide Depot
6 A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
7 Phase II Study of RAD001 Plus Octreotide Depot in Patients With Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma (Carcinoid, Islet Cell) Completed NCT00113360 Phase 2 RAD001;Octreotide Depot
8 A Phase II Trial of Bay 43-9006 in Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
9 A Phase II Trial of ZD1839 (Iressa®) in Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
10 A Phase II Study of CCI-779 in Metastatic Neuroendocrine Carcinomas Completed NCT00093782 Phase 2 temsirolimus
11 A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
12 Perfusion CT as Predictive Biomarker in a Phase II Study of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors Completed NCT02101918 Phase 2
13 Phase II Trial Of Thalidomide In Patients With Low Grade Neuroendocrine Tumors (Carcinoid and Islet Cell Cancers) Completed NCT00027638 Phase 2 thalidomide
14 A Randomised Phase II Study Comparing Capecitabine Plus Streptozocin With or Without Cisplatin Chemotherapy as Treatment for Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
15 A Phase II Study of Isolated Hepatic Perfusion (IHP) With Melphalan for Metastatic Unresectable Cancers of the Liver Completed NCT00019786 Phase 2 isolated perfusion;melphalan
16 Study of First-Line Therapy Comprising Leucovorin Calcium, Fluorouracil, and Irinotecan (FOLFIRI) in Patients With Progressive Locally Advanced or Metastatic Duodenal-Pancreatic Endocrine Tumors Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
17 A Phase II Clinical and Biologic Study of AMG 706 and Octreotide in Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
18 A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver Completed NCT00096083 Phase 2 isolated perfusion;melphalan
19 Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II. Recruiting NCT02230176 Phase 2 Sunitinib;177Lu-DOTA0-Tyr3-Octreotate
20 Phase 2 Single-Arm Study of Nanoliposomal Irinotecan With Fluorouracil and Leucovorin in Refractory Advanced High Grade Neuroendocrine Cancer of GI, Unknown or Pancreatic Origin Recruiting NCT03736720 Phase 2 Fluorouracil;Leucovorin;Liposomal Irinotecan
21 Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced G3 Non-small Cell Gastroenteropancreatic Neuroendocrine Carcinomas Recruiting NCT02595424 Phase 2 Capecitabine;Carboplatin;Cisplatin;Etoposide;Temozolomide
22 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
23 A Phase II Study of Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525082 Phase 2 capecitabine;temozolomide
24 Phase II Study of Single Agent Regorafenib in Patients With Advanced/Metastatic Neuroendocrine Tumors Active, not recruiting NCT02259725 Phase 2 regorafenib
25 A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumors (PNET) Active, not recruiting NCT01465659 Phase 1, Phase 2 temozolomide;pazopanib hydrochloride
26 Randomized Phase II Study of Everolimus Alone Versus Everolimus Plus Bevacizumab in Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01229943 Phase 2 Everolimus;Octreotide Acetate
27 A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01824875 Phase 2 temozolomide;capecitabine
28 A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET) Suspended NCT02893930 Phase 2 Sapanisertib
29 Phase II Trial of FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas Terminated NCT03042780 Phase 2 FOLFIRINOX;Granulocyte colony-stimulating factor (G-CSF)
30 A Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Adjuvant Everolimus Following the Resection of Metastatic Pancreatic Neuroendocrine Tumors to the Liver Terminated NCT02031536 Phase 2 everolimus
31 Phase II Study of Depsipeptide in Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2 romidepsin
32 Phase II Evaluation of Real-Time, Pharmacokinetically Guided Everolimus in Patients With Hormone Receptor Positive Breast Cancer, Pancreatic Neuroendocrine Tumors (PNET), and Renal Cell Carcinoma Terminated NCT02273752 Phase 2 Everolimus
33 Clinical Trial of Sir-Spheres® in Patients With Symptomatic or Progressive Hepatic Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
34 Phase II Study of Vatalanib and Octreotide in Patients With Progressive Low-Grade Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
35 Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Metastatic or Incurable Neuroendocrine Tumors Withdrawn NCT00003514 Phase 2 antineoplaston A10;antineoplaston AS2-1
36 Phase II Study of Dovitinib (TKI-258) in Progressive, Well-Differentiated Pancreatic Neuroendocrine Tumors With and Without Prior VEGF-Inhibitor Therapy Withdrawn NCT02108782 Phase 2 dovitinib lactate
37 Phase I Clinical Trial of Temsirolimus and Vinorelbine in Advanced Solid Tumors. Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
38 Phase I Study of Anti-IGF-1R Monoclonal Antibody, IMC-A12, and mTOR Inhibitor, Everolimus, in Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
39 A Phase I Trial of Herceptin and Interleukin-12 Completed NCT00004074 Phase 1
40 A Phase I Trial of the mTOR Inhibitor RAD001 in Combination With VEGF Receptor Tyrosine Kinase Inhibitor PTK787/ZK 222584 in Patients With Advanced Solid Tumors Completed NCT00655655 Phase 1 everolimus;vatalanib
41 A Phase I, Open Label, Maximum Tolerated Dose-Finding Study to Evaluate the Safety and Tolerability of 90Y-DOTA-tyr3-Octreotide Administered by Intravenous Infusion to Children With Refractory Somatostatin-Receptor Positive Tumors Completed NCT00049023 Phase 1
42 A Phase I Study of Intraperitoneal Oxaliplatin Alone and in Combination With Intraperitoneal Floxuridine and Leucovorin in Patients With Advanced Metastatic Cancer Confined to the Peritoneal Cavity Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
43 A Phase I, Open-Label, Maximum Tolerated Single-Cycle and Four-Cycle Dose-Finding Study to Evaluation the Safety and Tolerability of 90Y-SMT 487 Administered by Intravenous Infusion to Subjects With Refractory Somatostatin-Receptor Positive Tumors Completed NCT00006368 Phase 1
44 A Phase I, Pharmacokinetic, and Biologic Correlative Study of R115777 (NSC 702818) and Herceptin in Patients With Advanced Cancer Completed NCT00005842 Phase 1 tipifarnib
45 A Phase Ib Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Metastatic Pancreatic Adenocarcinoma Active, not recruiting NCT02231723 Phase 1 BBI608;Nab-paclitaxel;Gemcitabine;Oxaliplatin;Leucovorin;Irinotecan;Fluorouracil;MM-398
46 A Phase I Study of [111In-DTPA-D-Phe]-Octreotide in Patients With Refractory Malignancies Expressing Somatostatin Receptors Terminated NCT00002947 Phase 1
47 A Phase 1 Study of Veliparib (ABT-888) in Combination With Capecitabine and Temozolomide in Advanced Well-Differentiated Neuroendocrine Tumors Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
48 An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment Completed NCT00428220 sunitinib
49 CYCORE: Cyberinfrastructure for Comparative Effectiveness Research - Feasibility Trial Recruiting NCT01365169
50 Biospecimen Resource for Pancreas Research, a Data & Tissue Bank (Also Known as a Bio-repository, Bio-bank, Data & Tissue Database, Data & Tissue Registry, Etc.) to Help Advance Research in Pancreas Disease Recruiting NCT00830557

Search NIH Clinical Center for Pancreatic Endocrine Carcinoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Dacarbazine

Cochrane evidence based reviews: carcinoma, islet cell

Genetic Tests for Pancreatic Endocrine Carcinoma

Anatomical Context for Pancreatic Endocrine Carcinoma

MalaCards organs/tissues related to Pancreatic Endocrine Carcinoma:

40
Pancreas, Pituitary, Liver, Lung, Breast, Thyroid, Ovary

Publications for Pancreatic Endocrine Carcinoma

Articles related to Pancreatic Endocrine Carcinoma:

(show top 50) (show all 144)
# Title Authors PMID Year
1
RBL1 (p107) functions as tumor suppressor in glioblastoma and small-cell pancreatic neuroendocrine carcinoma in Xenopus tropicalis. 61
32001819 2020
2
A phase II trial of everolimus in patients with advanced pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-containing chemotherapy (NECTOR trial). 61
31986515 2020
3
A Clinicopathologic and Molecular Update of Pancreatic Neuroendocrine Neoplasms With a Focus on the New World Health Organization Classification. 61
31509453 2019
4
LARGE CELL METASTATIC PANCREATIC NEUROENDOCRINE CARCINOMA TREATED WITH SOMATOSTATIN ANALOGUES - CASE REPORT AND LITERATURE REVIEW. 61
32010361 2019
5
The eighth edition of the American Joint Committee on Cancer (AJCC) distant metastases (M) stage classification for metastatic pancreatic neuroendocrine tumors might be feasible for metastatic pancreatic ductal adenocarcinomas. 61
31357196 2019
6
Hepatobiliary and Pancreatic: A procalcitonin-secreting and calcitonin-secreting pancreatic neuroendocrine carcinoma. 61
30663800 2019
7
Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately. 61
30863939 2019
8
Surgical resection of the primary tumor leads to prolonged survival in metastatic pancreatic neuroendocrine carcinoma. 61
30898132 2019
9
Textural analysis on contrast-enhanced CT in pancreatic neuroendocrine neoplasms: association with WHO grade. 61
30182253 2019
10
Adrenocorticotropin Hormone Secreting Carcinoma of the Pancreas: A Case Report. 61
31236541 2019
11
Neoplasms of the Neuroendocrine Pancreas: An Update in the Classification, Definition, and Molecular Genetic Advances. 61
29912000 2019
12
[A Case of Successful Treatment of Recurrent Liver Metastases from Mixed Adenoneuroendocrine Carcinoma of the Pancreas with Everolimus Administration]. 61
30587736 2018
13
The Levels of Tumor Markers in Pancreatic Neuroendocrine Carcinoma and Their Values in Differentiation Between Pancreatic Neuroendocrine Carcinoma and Pancreatic Ductal Adenocarcinoma. 61
30308534 2018
14
TFE3 is a diagnostic marker for solid pseudopapillary neoplasms of the pancreas. 61
30030118 2018
15
Cutaneous metastases of pancreatic neuroendocrine carcinoma. 61
30246953 2018
16
The differentiation of pancreatic neuroendocrine carcinoma from pancreatic ductal adenocarcinoma: the values of CT imaging features and texture analysis. 61
30333055 2018
17
Impressive Response to Tandem Treatment With [90Y]DOTATOC and [177Lu]DOTATOC in Grade 3 Pancreatic Neuroendocrine Carcinoma. 61
29742602 2018
18
Metachronous gastric metastasis from lung primary, with synchronous pancreatic neuroendocrine carcinoma. 61
29988660 2018
19
Pancreatic neuroendocrine carcinomas reveal a closer relationship to ductal adenocarcinomas than to neuroendocrine tumors G3. 61
29596894 2018
20
An Advanced Well-differentiated Pancreatic Neuroendocrine Carcinoma (NET-G3) Associated with Von Hippel-Lindau Disease. 61
29491307 2018
21
Selective internal radiation therapy: an effective treatment for hormonal syndromes in pancreatic neuroendocrine tumors. 61
31293777 2018
22
[Conversion Surgery after Etoposide/Cisplatin(EP)Therapy for Huge Pancreatic Neuroendocrine Carcinoma - A Case Report]. 61
29650928 2018
23
Laparoscopic Resection of a Pancreatic β Cell Tumor in a Dog. 61
28892425 2017
24
Differences between Grades G1 and G2 Hypovascular Pancreatic Neuroendocrine Tumors and Pancreatic Neuroendocrine Carcinoma. 61
28926309 2017
25
Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study. 61
28455360 2017
26
Differentiation of pancreatic neuroendocrine carcinoma from pancreatic ductal adenocarcinoma using magnetic resonance imaging: The value of contrast-enhanced and diffusion weighted imaging. 61
28487490 2017
27
Pancreatic neuroendocrine carcinoma with exocrine differentiation in a young cat. 61
28363254 2017
28
Clinical outcomes and prognostic factors of resected pancreatic neuroendocrine neoplasms: A single-center experience in China. 61
28521422 2017
29
Characterization of single lesion nonfunctioning pancreatic neuroendocrine carcinoma via computed tomography. 61
28454379 2017
30
The prognostic influence of the proliferative discordance in metastatic pancreatic neuroendocrine carcinoma revealed by peptide receptor radionuclide therapy: Case report and review of literature. 61
28178157 2017
31
Targeted Therapies Provide Treatment Options for Poorly Differentiated Pancreatic Neuroendocrine Carcinomas. 61
27838688 2017
32
Pancreatic neuroendocrine neoplasms at magnetic resonance imaging: comparison between grade 3 and grade 1/2 tumors. 61
28331340 2017
33
[Surgical treatment and prognosis of pancreatic neuroendocrine carcinoma]. 61
27998470 2016
34
Granulomatous Insulitis as a Cause of Acute-Onset Insulin-Dependent Diabetes Mellitus in a Patient With a Pancreatic Endocrine Carcinoma. 61
27160433 2016
35
Clinical characteristics and management of insulin-producing neuroendocrine carcinomas. 61
27821028 2016
36
Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma. 61
27142424 2016
37
Pathology and Surgical Treatment of High-Grade Pancreatic Neuroendocrine Carcinoma: an Evolving Landscape. 61
26984415 2016
38
Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study. 61
26678407 2016
39
A malignant cause of hypoglycaemia: a metastatic insulin-secreting pancreatic neuroendocrine carcinoma. 61
26994053 2016
40
A giant non-functioning pancreatic neuroendocrine carcinoma founded as an incidentaloma successfully treated with pancreatoduodenectomy. 61
27713785 2016
41
Intraductal Tubulopapillary Neoplasm of the Pancreas Masquerading as Pancreatic Neuroendocrine Carcinoma: Review of the Literature with a Case Report. 61
27459312 2016
42
Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: a single-center retrospective study. 61
26378090 2015
43
Pancreatic neuroendocrine tumor in a child of 3.5 years old. 61
24974212 2015
44
Pancreatic neuroendocrine carcinoma diagnosed using endoscopic ultrasound-guided fine needle aspiration: A case report and literature review. 61
26612453 2015
45
Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma. 61
25755102 2015
46
Treatment of High-Grade Metastatic Pancreatic Neuroendocrine Carcinoma with FOLFIRINOX. 61
25662891 2015
47
The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. 61
25723112 2015
48
A Rare Case of Calf Muscle Metastasis from a Non-Functional Pancreatic Neuroendocrine Carcinoma. 61
26060551 2015
49
[Appleby operation for locally advanced tumour of the pancreatic body and tail--a video demonstration]. 61
25874466 2015
50
[Pancreatic neuroendocrine carcinoma: report of a case]. 61
26161192 2015

Variations for Pancreatic Endocrine Carcinoma

Expression for Pancreatic Endocrine Carcinoma

Search GEO for disease gene expression data for Pancreatic Endocrine Carcinoma.

Pathways for Pancreatic Endocrine Carcinoma

Pathways related to Pancreatic Endocrine Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.26 NCAM1 INS AFP
2 11.26 SSTR5 SSTR2 SST GCG

GO Terms for Pancreatic Endocrine Carcinoma

Cellular components related to Pancreatic Endocrine Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 SST SERPINA3 PTHLH PPY INS GCG
2 endoplasmic reticulum lumen GO:0005788 9.46 MEN1 INS GCG AFP
3 secretory granule lumen GO:0034774 9.43 SERPINA3 INS GCG
4 extracellular region GO:0005576 9.36 SST SPINK5 SERPINA3 PTHLH PPY NCAM1

Biological processes related to Pancreatic Endocrine Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.55 SSTR5 SSTR2 SST PTHLH MEN1
2 neuropeptide signaling pathway GO:0007218 9.5 SSTR5 SSTR2 PPY
3 osteoblast development GO:0002076 9.37 PTHLH MEN1
4 negative regulation of blood vessel diameter GO:0097756 9.26 INS CHGA
5 G protein-coupled receptor signaling pathway GO:0007186 9.23 SSTR5 SSTR2 SST PTHLH PPY INS
6 somatostatin signaling pathway GO:0038170 8.96 SSTR5 SSTR2

Molecular functions related to Pancreatic Endocrine Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.1 SST PTHLH PPY INS GCG GAST
2 somatostatin receptor activity GO:0004994 8.96 SSTR5 SSTR2

Sources for Pancreatic Endocrine Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....